Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE rejects Amgen’s Repatha in draft guidance

November 18, 2015
Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol

NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.   

News

NICE rejects Roche’s Kadcyla for NHS; price still too high

November 17, 2015
Manufacturing and Production, Sales and Marketing Cancer Drugs Fund, Kadcyla, NHS England, NICE, Roche

NICE has published final draft guidance on Roche’s Kadcyla as a breast cancer treatment, deciding that the drug’s price remains …

News
Jinarc

Otsuka kidney drug earns first NICE nod

October 28, 2015
Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …

News
bmss_orencia_was_recommended_in_draft_guidance

NICE recommends four treatments for arthritis in children

October 22, 2015
Medical Communications, Research and Development NICE, arthritis, jia

 UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …

News
bmss_orencia_was_recommended_in_draft_guidance

NICE recommends four treatments for arthritis in children

October 22, 2015
Medical Communications, Research and Development NICE, arthritis, jia

 UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …

News
Ezetrol

NICE issues draft guidance for MSD’s Ezetrol

October 21, 2015
Sales and Marketing MSD, NICE, cardiovascular disease, ezetimibie, ezetrol, high cholesterol

NICE has published draft guidance recommending MSD’s Ezetrol as an option for some adults with high cholesterol.  The guidance updates …

News

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
NHS sign

NICE requests more evidence on Duchenne muscular dystrophy therapy

October 16, 2015
Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren

NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …

News
PM David Cameron

ABPI hits back at Prime Minister’s criticism of high drug prices

October 15, 2015
Sales and Marketing ABPI, Drug pricing, Duchenne Muscular Dystrophy, NICE, Translarna, ataluren, david cameron, prime minister, rare disease

The ABPI has responded to comments made by UK Prime Minister David Cameron during yesterday’s Prime Minster’s Questions, in which …

News
oma_nice

NICE launches new service to speed NHS adoption of health technologies

October 13, 2015
Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, OMA, market access, office for market access

NICE is introducing a new service, the Office for Market Access (OMA), to work with industry to speed up NHS …

News
keytruda3-web

MSD’s Keytruda receives green light from NICE for NHS use

October 12, 2015
Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer

The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …

News
merckincweb

NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment

October 7, 2015
Research and Development Merck, NHS, NICE, keytruda, skin cancer

The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …

News
gilead-sciences

NICE approves first in new class of leukaemia drugs

September 24, 2015
Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig

NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …

News
Abraxane

NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’

September 17, 2015
Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer

NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …

News
Farydak

NICE rejects Farydak for multiple myeloma

September 16, 2015
Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026